Editorial comment to: Effectiveness of simultaneous electroacupuncture stimulation on the tibial and ilioinguinal-iliohypogastric nerves in the treatment of refractory overactive bladder syndrome in women

Acknowledgments

None.

Statement of ethics

Not applicable.

Conflicts of interest statement

DB is a member of the Early Career Editorial Board of Current Urology and confirms no involvement in any stage of this article’s review process, ensuring unbiased editorial decision-making. EFA: Laborie (Consultant and Speaker Honorarium), Recordati (Speaker Honorarium), Pierre Fabre (Speaker Honorarium).

Funding source

None.

Author contributions

DB and EFA revised the literature and conceived the paper; DB drafted the manuscript.

Data availability

All data generated or analyzed during this study are included in this published article.

References

[1] McGuire EJ, Zhang SC, Horwinski ER, et al. Treatment of motor and sensory detrusor instability by electrical stimulation. J Urol 1983;129:78-79.

[2] Cooperberg MR, Stoller ML. Percutaneous neuromodulation. Urol Clin North Am 2005;32:71-78, vii.

[3] Finazzi Agrò E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: A randomized, double-blind, placebo-controlled trial. J Urol 2010; 184(5):2001-2006.

[4] Peters KM, Carrico DJ, Wooldridge LS, Miller CJ, MacDiarmid SA. Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol 2013; 189(6):2194-2201.

[5] Bianchi D, Iacovelli V, Parisi I, et al. Real-life data on long-term follow-up of patients successfully treated with percutaneous tibial nerve stimulation. Minerva Urol Nephrol 2021; 73(2):260-264.

[6] Lv T, Fang W, Si J, et al. Effectiveness of simultaneous electroacupuncture stimulation on the tibial and ilioinguinal-iliohypogastric nerves in the treatment of refractory overactive bladder syndrome in women. Curr Urol 2025; 19(2):110-116.

[7] Stampas A, Korupolu R, Lee KH, Salazar B, Khavari R. Reduction of overactive bladder medications in spinal cord injury with self-administered neuromodulation: A randomized trial. J Urol 2024; 212(6):800-810.

[8] Dhaliwal P, Wagg A. Overactive bladder: Strategies to ensure treatment compliance and adherence. Clin Interv Aging 2016;11:755-760.

[9] Abrar M, Stroman L, Malde S, Solomon E, Sahai A. Predictors of poor response and adverse events following botulinum toxin-A for refractory idiopathic overactive bladder. Urology 2020;135:32-37.

[10] Van den Ende M, Apostolidis A, Sinha S, et al. Should we be treating affective symptoms, like anxiety and depression which may be related to LUTD in patients with OAB? ICI-RS 2024. Neurourol Urodyn 2025; 44(3):661-667.

[11] Chancellor MB, Migliaccio-Walle K, Bramley TJ, Chaudhari SL, Corbell C, Globe D. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther 2013; 35(11):1744-1751.

[12] Chapple CR, Wagg A, Harding C, et al. From clinical trials to routine practice: Are urodynamics still useful? Eur Urol 2025; 88(6):537-539.

[13] Averbeck MA, Gajewski JB, Finazzi-Agrò E, et al. Is our limited understanding of the effects of nerve stimulation resulting in poor outcomes and the need for better “rescue programming” in SNM and PTNS, and lost opportunities for new sites of stimulation? ICI-RS 2024. Neurourol Urodyn 2025; 44(3):676-682.